Physician profile
Joseph Husney
NPI 1770699647
$4,265.58
in general payments reported to CMS, 2019-2025
26 companies · $552 in 2025
The $552 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $555 · 2021: $591 · 2022: $830 · 2023: $696 · 2024: $413 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $592.17 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $570.80 | 2020-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $471.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $373.99 | 2019-2025 | Camzyos, Eliquis |
| Gilead Sciences, INC. | $318.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $294.11 | 2019-2025 | Pifeltro, Delstrigo |
| Sanofi-Aventis U.S. LLC | $287.67 | 2019-2022 | |
| Viiv Healthcare Company | $271.45 | 2022-2025 | Dovato |
| Pfizer INC. | $181.61 | 2019-2025 | |
| Abbvie INC. | $142.24 | 2020-2021 | |
| Astellas Pharma US INC | $132.71 | 2019-2023 | Myrbetriq |
| Renalytix Ai, INC. | $126.01 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Esperion Therapeutics, INC. | $79.90 | 2024-2025 | Nexletol |
| Aimmune Therapeutics, INC. | $72.96 | 2025 | Vowst |
| Allergan, INC. | $49.08 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $47.82 | 2022 | |
| Janssen Biotech, INC. | $38.64 | 2021-2022 | |
| Amgen INC. | $37.58 | 2019-2023 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.66 | 2019-2020 | |
| Genentech USA, INC. | $23.58 | 2020 | |
| Ironwood Pharmaceuticals, INC | $23.34 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.89 | 2021 | |
| Novo Nordisk INC | $20.35 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2022 | |
| Circassia INC. | $16.18 | 2019 | |
| Shire North American Group INC | $15.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Husney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.